Advertisement
Elicera Therapeutics receives Notice of Allowance for Chinease patent
Elicera Therapeutics has received a Notice of Allowance from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies.
Once granted, the patent can be kept in force until 2036.
“iTANK is one of our key assets and together with the recently approved European patent we now have strong protection for the technology. China is one of the most important markets in the CAR T-cell field so this is very significant for us,” says Jamal El-Mosleh , CEO of Elicera Therapeutics.
Photo of Jamal El-Mosleh
Published: September 12, 2023